z-logo
open-access-imgOpen Access
Evaluation of a new VMAT QA device, or the “X” and “O” array geometries
Author(s) -
Feygelman Vladimir,
Zhang Geoffrey,
Stevens Craig,
Nelms Benjamin E.
Publication year - 2011
Publication title -
journal of applied clinical medical physics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.83
H-Index - 48
ISSN - 1526-9914
DOI - 10.1120/jacmp.v12i2.3346
Subject(s) - imaging phantom , detector , normalization (sociology) , physics , optics , dosimetry , calibration , computer science , nuclear medicine , medicine , quantum mechanics , sociology , anthropology
We introduce a logical process of three distinct phases to begin the evaluation of a new 3D dosimetry array. The array under investigation is a hollow cylinder phantom with diode detectors fixed in a helical shell forming an “O” axial detector cross section (ArcCHECK), with comparisons drawn to a previously studied 3D array with diodes fixed in two crossing planes forming an “X” axial cross section (Delta 4 ). Phase I testing of the ArcCHECK establishes: robust relative calibration (response equalization) of the individual detectors, minor field size dependency of response not present in a 2D predecessor, and uncorrected angular response dependence in the axial plane. Phase II testing reveals vast differences between the two devices when studying fixed‐width full circle arcs. These differences are primarily due to arc discretization by the TPS that produces low passing rates for the peripheral detectors of the ArcCHECK, but high passing rates for the Delta 4 . Similar, although less pronounced, effects are seen for the test VMAT plans modeled after the AAPM TG119 report. The very different 3D detector locations of the two devices, along with the knock‐on effect of different percent normalization strategies, prove that the analysis results from the devices are distinct and noninterchangeable; they are truly measuring different things. The value of what each device measures, namely their correlation with – or ability to predict – clinically relevant errors in calculation and/or delivery of dose is the subject of future Phase III work. PACS number: 87.55Qr

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here